Trials / Completed
CompletedNCT03927781
Perioperative Pregabalin in Ureteroscopy: a Pilot
Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Missouri-Columbia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators propose a pilot clinical trial on the use of perioperative pregabalin in order to decrease ureteral stent related symptoms and decrease opioid usage after ureteroscopy with stent placement. Patients undergoing ureteroscopy with stent placement will receive a single dose of 300 mg pregabalin PO in the preoperative area. This work will assess safety and feasibility of studying this regimen at our institution, with the aim of performing a randomized, placebo-controlled, double-blinded study in the future.
Conditions
- Nephrolithiasis
- Urolithiasis
- Perioperative/Postoperative Complications
- Pain, Postoperative
- Pain, Acute
- Anesthesia
- Urologic Diseases
- Anesthesia Morbidity
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin 300mg | One 300mg capsule will be administered PO 1 hour before surgery |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2019-10-17
- Completion
- 2020-10-17
- First posted
- 2019-04-25
- Last updated
- 2021-04-19
- Results posted
- 2021-04-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03927781. Inclusion in this directory is not an endorsement.